Publications by authors named "G Requirand"
Multiple myeloma (MM) is a hematological malignancy characterized by an abnormal clonal proliferation of malignant plasma cells. Despite the introduction of novel agents that have significantly improved clinical outcome, most patients relapse and develop drug resistance. MM is characterized by genomic instability and a high level of replicative stress.
View Article and Find Full Text PDFArticle Synopsis
- - The case involves a patient with severe thrombocytosis, where no secondary causes were identified, and although there were no signs of myelofibrosis, the patient's megakaryocytes were notably small and abnormal.
- - Genetic analysis revealed a novel calreticulin (CALR) mutation (C105S), alongside mutations in ASXL1, U2AF1, and EZH2, all found in myeloid cells, leading to a diagnosis of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN).
- - Treatment with hydroxycarbamide was initiated due to high thrombosis risk, but as the patient's condition worsened, additional mutations (SETBP
Multiple myeloma (MM) is a hematologic cancer characterized by accumulation of malignant plasma cells in the bone marrow. To date, no definitive cure exists for MM and resistance to current treatments is one of the major challenges of this disease. The DNA helicase BLM, whose depletion or mutation causes the cancer-prone Bloom's syndrome (BS), is a central factor of DNA damage repair by homologous recombination (HR) and genomic stability maintenance.
View Article and Find Full Text PDFHuman multiple myeloma (MM) cell lines (HMCLs) have been widely used to understand the molecular processes that drive MM biology. Epigenetic modifications are involved in MM development, progression, and drug resistance. A comprehensive characterization of the epigenetic landscape of MM would advance our understanding of MM pathophysiology and may attempt to identify new therapeutic targets.
View Article and Find Full Text PDF